The recent news from Biogen-Idec of the success of their experimental drug BG-12 for relapsing-remitting multiple sclerosis is in many ways remarkable. Although BG-12 is not approved yet, here are seven things about it which challenge many of the widely held beliefs about how we should best discover drugs today.
Monthly Archives: April 2012
The recent fashion for asset-centric micro companies focussed on one development project is the logical end point for the strategy of virtuality, begun some 15 years ago and,